Kukje Pharma Statistics

Total Valuation

Kukje Pharma has a market cap or net worth of KRW 117.90 billion. The enterprise value is 138.72 billion.

Market Cap	117.90B
Enterprise Value	138.72B

Important Dates

The last earnings date was Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

Kukje Pharma has 20.36 million shares outstanding. The number of shares has decreased by -0.02% in one year.

Current Share Class	n/a
Shares Outstanding	20.36M
Shares Change (YoY)	-0.02%
Shares Change (QoQ)	+1.09%
Owned by Insiders (%)	12.77%
Owned by Institutions (%)	8.45%
Float	12.69M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.82
PB Ratio	1.33
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 45.86, with an EV/FCF ratio of -75.93.

EV / Earnings	381.69
EV / Sales	0.97
EV / EBITDA	45.86
EV / EBIT	n/a
EV / FCF	-75.93

Financial Position

The company has a current ratio of 1.07, with a Debt / Equity ratio of 0.31.

Current Ratio	1.07
Quick Ratio	0.58
Debt / Equity	0.31
Debt / EBITDA	9.14
Debt / FCF	-15.14
Interest Coverage	-0.43

Financial Efficiency

Return on equity (ROE) is 0.47% and return on invested capital (ROIC) is -0.35%.

Return on Equity (ROE)	0.47%
Return on Assets (ROA)	-0.25%
Return on Capital (ROIC)	-0.35%
Revenue Per Employee	572.68M
Profits Per Employee	1.46M
Employee Count	249
Asset Turnover	0.94
Inventory Turnover	3.25

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.92% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+9.92%
50-Day Moving Average	5,447.20
200-Day Moving Average	5,408.30
Relative Strength Index (RSI)	56.17
Average Volume (20 Days)	888,086

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kukje Pharma had revenue of KRW 142.60 billion and earned 363.44 million in profits. Earnings per share was 17.02.

Revenue	142.60B
Gross Profit	72.59B
Operating Income	-607.28M
Pretax Income	-23.99M
Net Income	363.44M
EBITDA	3.02B
EBIT	-607.28M
Earnings Per Share (EPS)	17.02

Full Income Statement

Balance Sheet

The company has 6.84 billion in cash and 27.65 billion in debt, giving a net cash position of -20.81 billion or -1,021.94 per share.

Cash & Cash Equivalents	6.84B
Total Debt	27.65B
Net Cash	-20.81B
Net Cash Per Share	-1,021.94
Equity (Book Value)	88.75B
Book Value Per Share	4,358.05
Working Capital	3.26B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 17.87 million and capital expenditures -1.84 billion, giving a free cash flow of -1.83 billion.

Operating Cash Flow	17.87M
Capital Expenditures	-1.84B
Free Cash Flow	-1.83B
FCF Per Share	-89.72

Full Cash Flow Statement

Margins

Gross margin is 50.91%, with operating and profit margins of -0.43% and 0.25%.

Gross Margin	50.91%
Operating Margin	-0.43%
Pretax Margin	-0.02%
Profit Margin	0.25%
EBITDA Margin	2.12%
EBIT Margin	-0.43%
FCF Margin	-1.28%

Dividends & Yields

Kukje Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.02%
Shareholder Yield	0.02%
Earnings Yield	0.29%
FCF Yield	-1.55%

Stock Splits

The last stock split was on March 17, 2023. It was a forward split with a ratio of 1.05.

Last Split Date	Mar 17, 2023
Split Type	Forward
Split Ratio	1.05

Scores

Kukje Pharma has an Altman Z-Score of 1.78. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.78
Piotroski F-Score	n/a